Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

Wilkie M. et al, (2020), Vaccine, 38, 779 - 789

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16

A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY

Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A

Wajja A. et al, (2018)

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy

Fletcher HA. et al, (2018), F1000Research, 7, 485 - 485

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

Wajja A. et al, (2017), PLOS Neglected Tropical Diseases, 11, e0005440 - e0005440

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

Minhinnick A. et al, (2016), Vaccine, 34, 1412 - 1421

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity

Minhinnick A. et al, (2016), Journal of Infectious Diseases, 213, 824 - 830

S40 Optimisation of a human BCG challenge model

Wilkie MEM. et al, (2015), Thorax, 70, A27.1 - A27

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

Sheehan S. et al, (2015), PLOS ONE, 10, e0141687 - e0141687

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

Ndiaye BP. et al, (2015), The Lancet Respiratory Medicine, 3, 190 - 200

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses

Tameris M. et al, (2014), PLoS ONE, 9, e87340 - e87340

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

Dieye TN. et al, (2013), PLoS ONE, 8, e67177 - e67177

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Tameris MD. et al, (2013), The Lancet, 381, 1021 - 1028

Capacity building for tuberculosis vaccine clinical trials in South Africa and Senegal

Vermaak S., (2012), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 17, 39 - 39

Include forthcoming?